RU2008143554A - Комбинации терапевтических агентов для лечения рака - Google Patents
Комбинации терапевтических агентов для лечения рака Download PDFInfo
- Publication number
- RU2008143554A RU2008143554A RU2008143554/15A RU2008143554A RU2008143554A RU 2008143554 A RU2008143554 A RU 2008143554A RU 2008143554/15 A RU2008143554/15 A RU 2008143554/15A RU 2008143554 A RU2008143554 A RU 2008143554A RU 2008143554 A RU2008143554 A RU 2008143554A
- Authority
- RU
- Russia
- Prior art keywords
- inhibitor
- kinase inhibitor
- kinase
- tyrosine kinase
- heterocyclic radical
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 claims abstract 47
- 229940043355 kinase inhibitor Drugs 0.000 claims abstract 34
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims abstract 34
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims abstract 29
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims abstract 26
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims abstract 23
- 239000003795 chemical substances by application Substances 0.000 claims abstract 17
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims abstract 17
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract 16
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract 16
- 230000006907 apoptotic process Effects 0.000 claims abstract 14
- 239000013543 active substance Substances 0.000 claims abstract 13
- 229940124291 BTK inhibitor Drugs 0.000 claims abstract 10
- 229940125814 BTK kinase inhibitor Drugs 0.000 claims abstract 10
- 229940123856 Glycogen synthase kinase 3 inhibitor Drugs 0.000 claims abstract 10
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 claims abstract 10
- 239000003572 glycogen synthase kinase 3 inhibitor Substances 0.000 claims abstract 10
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims abstract 10
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims abstract 10
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims abstract 9
- 229940124647 MEK inhibitor Drugs 0.000 claims abstract 9
- 229940122907 Phosphatase inhibitor Drugs 0.000 claims abstract 9
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims abstract 9
- 229940076850 Tyrosine phosphatase inhibitor Drugs 0.000 claims abstract 9
- 230000000340 anti-metabolite Effects 0.000 claims abstract 9
- 229940100197 antimetabolite Drugs 0.000 claims abstract 9
- 239000002256 antimetabolite Substances 0.000 claims abstract 9
- 229940121649 protein inhibitor Drugs 0.000 claims abstract 9
- 239000012268 protein inhibitor Substances 0.000 claims abstract 9
- 150000003431 steroids Chemical class 0.000 claims abstract 9
- 150000001875 compounds Chemical class 0.000 claims abstract 8
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims abstract 5
- 229940123877 Aurora kinase inhibitor Drugs 0.000 claims abstract 5
- 229940126074 CDK kinase inhibitor Drugs 0.000 claims abstract 5
- 229940122739 Calcineurin inhibitor Drugs 0.000 claims abstract 5
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 claims abstract 5
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 claims abstract 5
- 101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 claims abstract 5
- 101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 claims abstract 5
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 claims abstract 5
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 claims abstract 5
- 229940094664 Cysteine protease inhibitor Drugs 0.000 claims abstract 5
- 108020004414 DNA Proteins 0.000 claims abstract 5
- 239000012625 DNA intercalator Substances 0.000 claims abstract 5
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims abstract 5
- 101800003838 Epidermal growth factor Proteins 0.000 claims abstract 5
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 claims abstract 5
- 102000001267 GSK3 Human genes 0.000 claims abstract 5
- 102000003964 Histone deacetylase Human genes 0.000 claims abstract 5
- 108090000353 Histone deacetylase Proteins 0.000 claims abstract 5
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 claims abstract 5
- 101000624643 Homo sapiens M-phase inducer phosphatase 3 Proteins 0.000 claims abstract 5
- 101000580039 Homo sapiens Ras-specific guanine nucleotide-releasing factor 1 Proteins 0.000 claims abstract 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims abstract 5
- 101000729945 Homo sapiens Serine/threonine-protein kinase PLK2 Proteins 0.000 claims abstract 5
- 208000037147 Hypercalcaemia Diseases 0.000 claims abstract 5
- 229940113306 Ligase inhibitor Drugs 0.000 claims abstract 5
- 102100023330 M-phase inducer phosphatase 3 Human genes 0.000 claims abstract 5
- 229940083338 MDM2 inhibitor Drugs 0.000 claims abstract 5
- 239000012819 MDM2-Inhibitor Substances 0.000 claims abstract 5
- 101100523539 Mus musculus Raf1 gene Proteins 0.000 claims abstract 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims abstract 5
- 102100031462 Serine/threonine-protein kinase PLK2 Human genes 0.000 claims abstract 5
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 claims abstract 5
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims abstract 5
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims abstract 5
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims abstract 5
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims abstract 5
- 239000003121 adenosine kinase inhibitor Substances 0.000 claims abstract 5
- 239000002671 adjuvant Substances 0.000 claims abstract 5
- 239000002168 alkylating agent Substances 0.000 claims abstract 5
- 229940100198 alkylating agent Drugs 0.000 claims abstract 5
- 239000004037 angiogenesis inhibitor Substances 0.000 claims abstract 5
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims abstract 5
- 239000005557 antagonist Substances 0.000 claims abstract 5
- 230000002280 anti-androgenic effect Effects 0.000 claims abstract 5
- 229940046836 anti-estrogen Drugs 0.000 claims abstract 5
- 230000001833 anti-estrogenic effect Effects 0.000 claims abstract 5
- 239000000051 antiandrogen Substances 0.000 claims abstract 5
- 239000003719 aurora kinase inhibitor Substances 0.000 claims abstract 5
- 239000011230 binding agent Substances 0.000 claims abstract 5
- 230000001276 controlling effect Effects 0.000 claims abstract 5
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims abstract 5
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims abstract 5
- 230000000694 effects Effects 0.000 claims abstract 5
- 230000002124 endocrine Effects 0.000 claims abstract 5
- 229940116977 epidermal growth factor Drugs 0.000 claims abstract 5
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims abstract 5
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims abstract 5
- 239000000328 estrogen antagonist Substances 0.000 claims abstract 5
- 229940045109 genistein Drugs 0.000 claims abstract 5
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims abstract 5
- 235000006539 genistein Nutrition 0.000 claims abstract 5
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims abstract 5
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims abstract 5
- 229940088597 hormone Drugs 0.000 claims abstract 5
- 239000005556 hormone Substances 0.000 claims abstract 5
- 230000000148 hypercalcaemia Effects 0.000 claims abstract 5
- 208000030915 hypercalcemia disease Diseases 0.000 claims abstract 5
- 239000000411 inducer Substances 0.000 claims abstract 5
- 108010042209 insulin receptor tyrosine kinase Proteins 0.000 claims abstract 5
- 239000000436 ligase inhibitor Substances 0.000 claims abstract 5
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims abstract 5
- 230000037361 pathway Effects 0.000 claims abstract 5
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims abstract 5
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims abstract 5
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims abstract 5
- 102000005962 receptors Human genes 0.000 claims abstract 5
- 108020003175 receptors Proteins 0.000 claims abstract 5
- 230000001105 regulatory effect Effects 0.000 claims abstract 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims abstract 5
- 201000010099 disease Diseases 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 230000002062 proliferating effect Effects 0.000 claims 18
- 238000000034 method Methods 0.000 claims 17
- 125000002947 alkylene group Chemical group 0.000 claims 14
- 229910052799 carbon Inorganic materials 0.000 claims 14
- 125000004432 carbon atom Chemical group C* 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 14
- 102000003923 Protein Kinase C Human genes 0.000 claims 12
- 108090000315 Protein Kinase C Proteins 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 11
- 108091006082 receptor inhibitors Proteins 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 8
- 206010033128 Ovarian cancer Diseases 0.000 claims 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 8
- 230000015572 biosynthetic process Effects 0.000 claims 8
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 8
- 201000005296 lung carcinoma Diseases 0.000 claims 8
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims 8
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims 8
- 201000001441 melanoma Diseases 0.000 claims 8
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 8
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 8
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- -1 di-substituted amino Chemical group 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 239000001301 oxygen Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000000547 substituted alkyl group Chemical group 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 239000011593 sulfur Substances 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 6
- 238000004806 packaging method and process Methods 0.000 claims 5
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 4
- 101100457333 Homo sapiens MAPK11 gene Proteins 0.000 claims 4
- 229940122696 MAP kinase inhibitor Drugs 0.000 claims 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 4
- 108700036166 Mitogen-Activated Protein Kinase 11 Proteins 0.000 claims 4
- 102100026929 Mitogen-activated protein kinase 11 Human genes 0.000 claims 4
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 claims 4
- 108091000080 Phosphotransferase Proteins 0.000 claims 4
- 229940116193 Protein phosphatase inhibitor Drugs 0.000 claims 4
- 101150046814 SAPK2 gene Proteins 0.000 claims 4
- 229940121742 Serine/threonine kinase inhibitor Drugs 0.000 claims 4
- 229930182558 Sterol Natural products 0.000 claims 4
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 claims 4
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 claims 4
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims 4
- 101710112791 Tyrosine-protein kinase JAK2 Proteins 0.000 claims 4
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims 4
- 101710112792 Tyrosine-protein kinase JAK3 Proteins 0.000 claims 4
- 229940123429 VEGFR tyrosine kinase inhibitor Drugs 0.000 claims 4
- 210000004404 adrenal cortex Anatomy 0.000 claims 4
- 229960002436 cladribine Drugs 0.000 claims 4
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 claims 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 4
- 229960005420 etoposide Drugs 0.000 claims 4
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims 4
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 4
- 239000003934 phosphoprotein phosphatase inhibitor Substances 0.000 claims 4
- 102000020233 phosphotransferase Human genes 0.000 claims 4
- 229910052697 platinum Inorganic materials 0.000 claims 4
- 229920000768 polyamine Polymers 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 claims 4
- 150000004492 retinoid derivatives Chemical class 0.000 claims 4
- 108010087686 src-Family Kinases Proteins 0.000 claims 4
- 102000009076 src-Family Kinases Human genes 0.000 claims 4
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 claims 4
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 claims 4
- 150000003432 sterols Chemical class 0.000 claims 4
- 235000003702 sterols Nutrition 0.000 claims 4
- IAHFWCOBPZCAEA-UHFFFAOYSA-N succinonitrile Chemical compound N#CCCC#N IAHFWCOBPZCAEA-UHFFFAOYSA-N 0.000 claims 4
- 238000003786 synthesis reaction Methods 0.000 claims 4
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 4
- 229960001278 teniposide Drugs 0.000 claims 4
- 102000009572 RNA Polymerase II Human genes 0.000 claims 3
- 108010009460 RNA Polymerase II Proteins 0.000 claims 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 claims 1
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 claims 1
- 229960004169 mitoxantrone hydrochloride Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- 102000010750 Metalloproteins Human genes 0.000 abstract 1
- 108010063312 Metalloproteins Proteins 0.000 abstract 1
- 230000001919 adrenal effect Effects 0.000 abstract 1
- 230000001054 cortical effect Effects 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78940106P | 2006-04-05 | 2006-04-05 | |
| US60/789,401 | 2006-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008143554A true RU2008143554A (ru) | 2010-05-10 |
Family
ID=38564304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008143554/15A RU2008143554A (ru) | 2006-04-05 | 2007-04-04 | Комбинации терапевтических агентов для лечения рака |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090099103A1 (enExample) |
| EP (1) | EP2004165A2 (enExample) |
| JP (1) | JP2009532497A (enExample) |
| KR (1) | KR20080108516A (enExample) |
| CN (1) | CN101415411A (enExample) |
| AU (1) | AU2007234379A1 (enExample) |
| BR (1) | BRPI0710291A2 (enExample) |
| CA (1) | CA2645242A1 (enExample) |
| MX (1) | MX2008012716A (enExample) |
| RU (1) | RU2008143554A (enExample) |
| WO (1) | WO2007115286A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2454118B (en) | 2007-06-06 | 2010-06-02 | Univ Maryland | Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
| AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| SG10201600077RA (en) | 2011-01-11 | 2016-02-26 | Glaxosmithkline Llc | Combination |
| RU2622015C2 (ru) | 2011-11-11 | 2017-06-08 | Новартис Аг | Способ лечения пролиферативного заболевания |
| MX2016004265A (es) * | 2013-10-01 | 2016-07-08 | Novartis Ag | Combinacion. |
| CN120577536A (zh) * | 2024-02-21 | 2025-09-02 | 上海交通大学医学院附属仁济医院 | 转运蛋白abca8阳性癌症相关成纤维细胞在制备诊断试剂盒中的用途及转运蛋白abca8在药物筛选中的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0119249D0 (en) * | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| MXPA04006822A (es) * | 2002-01-14 | 2004-12-08 | Novartis Ag | Combinaciones que comprenden epotilonas y anti-metabolitos. |
| MXPA05012464A (es) * | 2003-05-21 | 2006-01-30 | Novartis Ag | Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos. |
| CA2536140A1 (en) * | 2003-08-18 | 2005-02-24 | Pfizer Products Inc. | Dosing schedule for erbb2 anticancer agents |
| DK2253614T3 (da) * | 2004-04-07 | 2013-01-07 | Novartis Ag | IAP-inhibitorer |
| WO2006030947A1 (ja) * | 2004-09-13 | 2006-03-23 | Eisai R & D Management Co., Ltd. | スルホンアミド含有化合物の血管新生阻害物質との併用 |
| US20060148772A1 (en) * | 2004-11-16 | 2006-07-06 | Evans Astrid H | Combination |
| CN101080227B (zh) * | 2004-12-15 | 2011-08-31 | 诺瓦提斯公司 | 用于治疗癌症的治疗剂的组合 |
-
2007
- 2007-04-04 KR KR1020087024228A patent/KR20080108516A/ko not_active Withdrawn
- 2007-04-04 RU RU2008143554/15A patent/RU2008143554A/ru not_active Application Discontinuation
- 2007-04-04 BR BRPI0710291-7A patent/BRPI0710291A2/pt not_active IP Right Cessation
- 2007-04-04 CN CNA2007800121108A patent/CN101415411A/zh active Pending
- 2007-04-04 MX MX2008012716A patent/MX2008012716A/es not_active Application Discontinuation
- 2007-04-04 CA CA002645242A patent/CA2645242A1/en not_active Abandoned
- 2007-04-04 US US12/282,525 patent/US20090099103A1/en not_active Abandoned
- 2007-04-04 AU AU2007234379A patent/AU2007234379A1/en not_active Abandoned
- 2007-04-04 EP EP07781283A patent/EP2004165A2/en not_active Withdrawn
- 2007-04-04 JP JP2009504434A patent/JP2009532497A/ja active Pending
- 2007-04-04 WO PCT/US2007/065911 patent/WO2007115286A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2645242A1 (en) | 2007-10-11 |
| BRPI0710291A2 (pt) | 2011-08-09 |
| WO2007115286A2 (en) | 2007-10-11 |
| MX2008012716A (es) | 2008-10-14 |
| KR20080108516A (ko) | 2008-12-15 |
| CN101415411A (zh) | 2009-04-22 |
| US20090099103A1 (en) | 2009-04-16 |
| EP2004165A2 (en) | 2008-12-24 |
| AU2007234379A1 (en) | 2007-10-11 |
| WO2007115286A3 (en) | 2008-04-17 |
| JP2009532497A (ja) | 2009-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008143056A (ru) | КОМБИНАЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ Bcr-Abl/c-Kit/PDGF-R TK, ДЛЯ ЛЕЧЕНИЯ РАКА | |
| RU2008143553A (ru) | Комбинации терапевтических агентов для лечения рака | |
| RU2008143554A (ru) | Комбинации терапевтических агентов для лечения рака | |
| US6693125B2 (en) | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders | |
| JP7327802B2 (ja) | 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法 | |
| CN101415409B (zh) | 用于治疗癌症的治疗剂的组合 | |
| RU2009134223A (ru) | Комбинация lbh589 с другими терапевтическими средствами, предназначенная для лечения рака | |
| RU2010128239A (ru) | Комбинации терапевтических средств, предназначенных для лечения рака | |
| AU2015288381B2 (en) | Substituted 2-thioxo-imidazolidin-4-ones and spiro analogues thereof, active anti-cancer ingredient, pharmaceutical composition, medicinal preparation, method for treating prostate cancer | |
| Khan et al. | Identification of novel oxadiazole-based benzothiazole derivatives as potent inhibitors of α-glucosidase and urease: synthesis, in vitro bio-evaluation and their in silico molecular docking study | |
| US20160130222A1 (en) | Inhibitors of the mitf molecular pathway | |
| BRPI0518231A2 (pt) | derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica | |
| BRPI0413500A (pt) | compostos, processos para a sua preparação, composição farmacêutica que compreende os mesmos, utilização de um composto, métodos para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade | |
| WO2017100703A1 (en) | Ems analogues of lyn/src-tyrosine kinase inhibitors | |
| Ono et al. | Syntheses and evaluation of amidinobenzofuran derivatives as tryptase inhibitors | |
| Wang et al. | Trisubstituted pyrimidines as transient receptor potential vanilloid 1 (TRPV1) antagonists with improved solubility | |
| HUP0600032A2 (en) | Sodium channel modulators derived from 2-piperidylimidazoles | |
| RU2217420C1 (ru) | 2-r-7а-метил-3-(спироциклогекса-2,5-диен-4-он)-пергидроиндолины-1 | |
| GAYATHIRI et al. | DFT STUDIES OF OXAZOLE DERIVATIVE | |
| JP2007530546A5 (enExample) | ||
| TH138873A (th) | สารรวมทางเภสัชกรรมสำหรับการบำบัดรักษา และ/หรือ เคโมเซนซิบิไลเซชันของเนื้องอกที่ดื้อต่อยาต้านมะเร็ง | |
| TH74505A (th) | อนุพันธุ์ 1-[2h-1-เบนโซไพแรน-2-โอน-8-อิล]- พิเพอราซีน สำหรับการบำบัดอาการปวด | |
| TH81396B (th) | อนุพันธ์ของเพอริดีน-2-คาร์บอกซาไมด์เป็นยาต้านฤทธิ์ mglur5 | |
| TH75720A (th) | [4-(5-อะมิโนเมทิล-2-ฟลูออโร-ฟีนิล)-พิเพอริดิน-1-อิล]-(4-โบรโม-3-เมทิล-5-โพรพอกซี-ไทโอฟีน-2-อิล)-เมทาโนน ไฮโดรคลอไรด์ ใช้เป็นสารยับยั้งเอนไซม์ทริปเทสในมาสท์เซลล์ | |
| TH75721A (th) | ยาเม็ดกระจายตัวได้ที่ประกอบด้วยอนุพันธุ์ของกรดเบนโซอิค |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20110815 |